Literature DB >> 12501975

Cardiovascular complications in acromegaly: methods of assessment.

G Vitale1, R Pivonello, M Galderisi, A D'Errico, L Spinelli, G Lupoli, G Lombardi, A Colao.   

Abstract

Cardiac involvement is common in acromegaly. Evidence for cardiac hypertrophy, dilation and diastolic filling abnormalities has been widely reported in literature. Generally, ventricular hypertrophy is revealed by echocardiography but early data referred increased cardiac size by standard X-ray. Besides, echocardiography investigates cardiac function and value disease. There are new technologic advances in ultrasonic imaging. Pulsed Tissue Doppler is a new non-invasive ultrasound tool which extends Doppler applications beyond the analysis of intra-cardiac flow velocities until the quantitative assessment of the regional myocardial left ventricular wall motion, measuring directly velocities and time intervals of myocardium. The radionuclide techniques permit to study better the cardiac performance. In fact, diastolic as well as systolic function can be assessed at rest and at peak exercise by equilibrium radionuclide angiography. This method has a main advantage of providing direct evaluation of ventricular function, being operator independent. Coronary artery disease has been poorly studied mainly because of the necessity to perform invasive procedures. Only a few cases have been reported with heart failure study by coronarography and having alterations of perfusion which ameliorated after somatostatin analog treatment. More recently, a few data have been presented using perfusional scintigraphy in acromegaly, even if coronary artery disease does not seem very frequent in acromegaly. Doppler analysis of carotid arteries can be also performed to investigate atherosclerosis: however, patients with active acromegaly have endothelial dysfunction more than clear-cut atherosclerotic plaques. In conclusion, careful assessments of cardiac function, morphology and activity need in patients with acromegaly.

Entities:  

Mesh:

Year:  2001        PMID: 12501975     DOI: 10.1023/a:1020750514954

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  54 in total

1.  Cardiac dysfunction in acromegaly: evidence by pulsed wave tissue Doppler imaging.

Authors:  G Mercuro; S Zoncu; P Colonna; P Cherchi; S Mariotti; F Pigliaru; L Petrini; S Iliceto
Journal:  Eur J Endocrinol       Date:  2000-09       Impact factor: 6.664

2.  Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy.

Authors:  A Colao; R Baldelli; P Marzullo; E Ferretti; D Ferone; P Gargiulo; M Petretta; G Tamburrano; G Lombardi; A Liuzzi
Journal:  J Clin Endocrinol Metab       Date:  2000-01       Impact factor: 5.958

3.  Arrhythmia profile in acromegaly.

Authors:  G Kahaly; K V Olshausen; S Mohr-Kahaly; R Erbel; S Boor; J Beyer; J Meyer
Journal:  Eur Heart J       Date:  1992-01       Impact factor: 29.983

Review 4.  Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms.

Authors:  N B Schiller; P M Shah; M Crawford; A DeMaria; R Devereux; H Feigenbaum; H Gutgesell; N Reichek; D Sahn; I Schnittger
Journal:  J Am Soc Echocardiogr       Date:  1989 Sep-Oct       Impact factor: 5.251

Review 5.  Electrocardiogram in endocrine and metabolic disorders.

Authors:  B Surawicz; M L Mangiardi
Journal:  Cardiovasc Clin       Date:  1977

6.  Color Doppler myocardial imaging: a new technique for the assessment of myocardial function.

Authors:  G R Sutherland; M J Stewart; K W Groundstroem; C M Moran; A Fleming; F J Guell-Peris; R A Riemersma; L N Fenn; K A Fox; W N McDicken
Journal:  J Am Soc Echocardiogr       Date:  1994 Sep-Oct       Impact factor: 5.251

7.  Endothelial-dependent vascular effects of insulin and insulin-like growth factor I in the perfused rat mesenteric artery and aortic ring.

Authors:  H Y Wu; Y Y Jeng; C J Yue; K Y Chyu; W A Hsueh; T M Chan
Journal:  Diabetes       Date:  1994-08       Impact factor: 9.461

8.  Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis.

Authors:  D S Celermajer; K E Sorensen; V M Gooch; D J Spiegelhalter; O I Miller; I D Sullivan; J K Lloyd; J E Deanfield
Journal:  Lancet       Date:  1992-11-07       Impact factor: 79.321

9.  Early vascular alterations in acromegaly.

Authors:  Gregorio Brevetti; Paolo Marzullo; Antonio Silvestro; Rosario Pivonello; Gabriella Oliva; Carolina di Somma; Gaetano Lombardi; Annamaria Colao
Journal:  J Clin Endocrinol Metab       Date:  2002-07       Impact factor: 5.958

10.  Lung function in acromegaly.

Authors:  B D Harrison; K A Millhouse; M Harrington; J D Nabarro
Journal:  Q J Med       Date:  1978-10
View more
  6 in total

1.  Coagulation parameters and platelet function analysis in patients with acromegaly.

Authors:  A Colak; H Yılmaz; Y Temel; M Demirpence; N Simsek; İ Karademirci; U Bozkurt; E Yasar
Journal:  J Endocrinol Invest       Date:  2015-06-06       Impact factor: 4.256

2.  Effects of somatostatin analogues on acromegalic cardiomyopathy: results from a prospective study using cardiac magnetic resonance.

Authors:  F Bogazzi; M Lombardi; E Strata; G Aquaro; M Lombardi; C Urbani; V Di Bello; C Cosci; C Sardella; E Talini; E Martino
Journal:  J Endocrinol Invest       Date:  2010-02       Impact factor: 4.256

3.  Acromegaly-induced cardiomyopathy with dobutamine-induced outflow tract obstruction.

Authors:  Mahmoud A Abdelsalam; Todd B Nippoldt; Jeffrey B Geske
Journal:  BMJ Case Rep       Date:  2016-03-09

Review 4.  Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities.

Authors:  Rosario Pivonello; Renata S Auriemma; Ludovica F S Grasso; Claudia Pivonello; Chiara Simeoli; Roberta Patalano; Mariano Galdiero; Annamaria Colao
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

5.  N-terminal pro-brain natriuretic peptide in newly diagnosed acromegaly.

Authors:  S Arikan; M Bahceci; A Tuzcu; D Gokalp
Journal:  J Endocrinol Invest       Date:  2010-09       Impact factor: 4.256

6.  Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly.

Authors:  Renata S Auriemma; Ludovica F S Grasso; Mariano Galdiero; Maurizio Galderisi; Claudia Pivonello; Chiara Simeoli; Maria Cristina De Martino; Rosario Ferrigno; Mariarosaria Negri; Cristina de Angelis; Rosario Pivonello; Annamaria Colao
Journal:  Endocrine       Date:  2016-06-13       Impact factor: 3.633

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.